Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tsui Chern Cheah

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Bioanalysis|May 2, 2015
Ask the experts: method transferChristopher A James, Tsui Chern Cheah, John Perkins, et al.
Pharmacotherapy|September 28, 2007
Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignanciesParnian Zia-Amirhosseini, David D Hurd, Margaret Salfi, et al.
Arthritis Research & Therapy|August 21, 2015
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trialsWilliam Stohl, Joan T Merrill, R John Looney, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Bioanalysis|May 2, 2015
Ask the experts: method transferChristopher A James, Tsui Chern Cheah, John Perkins, et al.
Pharmacotherapy|September 28, 2007
Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignanciesParnian Zia-Amirhosseini, David D Hurd, Margaret Salfi, et al.
Arthritis Research & Therapy|August 21, 2015
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trialsWilliam Stohl, Joan T Merrill, R John Looney, et al.
Pageof 1